Summa Equity acquires cleanroom expert G-CON Manufacturing

Published: 21-Jul-2021

The US-based prefabricated cleanroom specialist has been acquired by Summa when they purchased a majority stake

Summa Equity Fund II has acquired a majority stake in G-CON, a leading US-based manufacturer of prefabricated cleanrooms used for manufacturing within the pharmaceuticals industry.

G-CON designs, builds and installs turnkey cGMP (Current Good Manufacturing Practice) compliant suites called PODs, for a global biopharma customer base focused on biologics, pharma, CDMO (contract development and manufacturing), and cell and gene therapy manufacturing.

Founded in 2009 in Texas, G-CON has developed a unique prefabricated cleanroom solution, which differs from traditional cleanroom facility structures due to the ease of scalability, mobility, and the ability to repurpose the PODs once the production process reaches the end of its lifecycle. The company has experienced strong growth and sold more than 300 cleanrooms since inception.

As the biopharma market evolves, emerging modalities, such as cell and gene therapy, and the need to rapidly scale manufacturing requirements, have driven the pressing demand for off-site built solutions, which can be manufactured, installed, and scaled quickly. The COVID-19 pandemic has underlined the need for uninterrupted off-site construction of cleanroom infrastructures.

G-CON has become a market leader in fulfilling this demand, with high quality, scalable and flexible manufacturing solutions, delivered within rapid and reliable delivery timelines. Its value proposition is particularly relevant to the growing and highly complex biologics and personalized medicine market, which have unique manufacturing requirements.

By addressing and disrupting the limitations of conventional manufacturing processes that many biopharma manufacturers face, G-CON is aligned with Summa's focus on solving global challenges, and its Changing Demographics theme, along with UN Sustainable Development Goals (SDGs) #3: "Ensure healthy lives and promote well-being for all at all ages", and #9: "Industry, innovation and infrastructure".

Summa is supporting the company in its journey to become a leading turnkey bioprocessing solution provider globally by expanding the product and service offering and establishing a local presence outside the USA.

Marika Vitiä, Director at Summa Equity, said: "This is a vitally important element of the healthcare value chain, ensuring that more of society has access to the right healthcare when they need it."

"We are extremely happy to partner with Summa Equity as their vision and activities support our purpose of helping more patients gain affordable medicines fast. With Summa's support we will expand our capabilities, service, and product offerings, to transform manufacturing capacity within the biopharmaceutical market. We look forward to working with the team to further accelerate the global adoption of our unique bioprocessing solutions," said Maik Jornitz, CEO of G-CON.

The transaction was completed on 15 July 2021.

You may also like